Novo Nordisk CEO Lars Fruergaard Jørgensen on Friday mentioned the corporate’s experimental weight reduction tablet, amycretin, may finally turn out to be a best-in-class remedy for weight problems.
The Danish drugmaker is racing to capitalize on the runaway success of its blockbuster weight reduction drug Wegovy by growing a brand new era of therapies for weight problems, together with extra handy and doubtlessly cheaper capsules.
His remarks got here in the future after Novo Nordisk impressed buyers with early-stage trial information on amycretin. Patients on the tablet misplaced about 13.1% of their weight after 12 weeks, Jørgensen mentioned on CNBC’s “Money Movers.”
That surpasses the 6% weight reduction seen in those that took Wegovy after the identical time interval. It additionally provides to the rising enthusiasm across the potential of weight reduction capsules.
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks throughout an interview in New York on Aug. 10, 2022.
Christopher Goodney | Bloomberg | Getty Images
Along with comfort for sufferers, capsules may assist alleviate a number of the provide constraints plaguing weight reduction injections. Wegovy, together with related medicine, has soared in demand and slipped into intermittent shortages over the previous yr on account of its potential to assist sufferers shed important weight over time.
“We believe in the future there’ll be different segments of anti-obesity treatments, with different patients having different preferences,” Jørgensen instructed CNBC. “Some will prefer an injectable and we really believe that once we can take a pill, it’s a very convenient offering.”
But these capsules will not be part of the market any time quickly. A midstage trial on amycretin will start within the second half of this yr, with outcomes anticipated in early 2026, the corporate mentioned Thursday.
In a separate interview with Reuters on Friday, Novo Nordisk’s head of growth Martin Holst Lange mentioned the corporate is comfy in with the ability to launch amycretin this decade.
Amycretin suppresses urge for food by concentrating on the identical intestine hormone that Wegovy mimics, which is called GLP-1. But amycretin additionally targets a pancreas hormone referred to as amylin, which impacts starvation.
U.S.-traded shares of Novo Nordisk rose as a lot as 8.3% on Thursday after the corporate launched the information, extending the previous yr’s 68% acquire. But the corporate’s inventory fell 2% on Friday.
Source: www.cnbc.com”